PMID- 32946536
OWN - NLM
STAT- MEDLINE
DCOM- 20201028
LR  - 20201028
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Lot quality assurance sampling to assess coverage and compliance following mass 
      drug administration to eliminate lymphatic filariasis in Fiji: A methodological 
      approach.
PG  - e0238622
LID - 10.1371/journal.pone.0238622 [doi]
LID - e0238622
AB  - BACKGROUND: Assessing the quality of mass drug administration (MDA) rounds is a 
      key component of lymphatic filariasis (LF) elimination programs. Routine 
      collection of administrative coverage is unreliable, especially when pockets with 
      low program coverage exist. To address this gap, we used lot quality assurance 
      sampling (LQAS) following the 10th annual LF-MDA round in Fiji to explore whether 
      there was any area in which target coverage was not reached. We also assessed the 
      level of drug compliance and satisfaction with the LF-MDA implementation 
      strategy. METHODOLOGY/PRINCIPAL FINDINGS: We conducted a cross-sectional 
      household survey in 3 divisions of Fiji. For LQAS, we defined 19 lots in 7 
      medical areas of the Suva sub-division and another 12 sub-divisions in the 
      Central, Northern, and Eastern Divisions. A sample of 16 randomly selected 
      household members was taken un each lot. We defined our decision rule as follows: 
      if more than 1 person in a given lot did not swallow the medication, coverage was 
      considered inadequate, i.e. less than 80%. Of the 7 lots in Suva sub-division and 
      12 lots in the 3 divisions, five and two lots, respectively, were identified as 
      having inadequate coverage. The overall program coverage estimated from 304 
      samples was 92%, which was higher than the reported administrative coverage of 
      82%. About 98% of interviewees were offered the medication and 96% swallowed it. 
      Non-participation arose from insufficient information on how to obtain the drugs. 
      At least 92% were satisfied with the LF-MDA implementation strategy. CONCLUSIONS: 
      Areas of low program coverage with results discordant with the reported 
      administrative coverage existed in both urban and rural settings. Drug compliance 
      and satisfaction were high, even after repeated rounds. We recommend increasing 
      efforts to deliver the service in those areas with inadequate program coverage, 
      as well as conducting timely coverage assessment through LQAS for corrective 
      action.
FAU - Rinamalo, Milika
AU  - Rinamalo M
AD  - Ministry of Health and Medical Services, Dinem House, Suva, Republic of Fiji.
FAU - Pezzoli, Lorenzo
AU  - Pezzoli L
AD  - Epidemiology Consultant, London, United Kingdom.
FAU - Kama, Mike
AU  - Kama M
AD  - Ministry of Health and Medical Services, Dinem House, Suva, Republic of Fiji.
FAU - Rafai, Eric
AU  - Rafai E
AD  - Ministry of Health and Medical Services, Dinem House, Suva, Republic of Fiji.
FAU - Kubuabola, Ilisapeci
AU  - Kubuabola I
AD  - College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, 
      Republic of Fiji.
FAU - Salusalu, Mosese
AU  - Salusalu M
AD  - College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, 
      Republic of Fiji.
FAU - Kim, Sung Hye
AU  - Kim SH
AD  - Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, 
      Liverpool, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Elephantiasis, Filarial/*drug therapy
MH  - Family Characteristics
MH  - Female
MH  - Fiji
MH  - Geography
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Lot Quality Assurance Sampling
MH  - Male
MH  - *Mass Drug Administration
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7500667
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/19 06:00
MHDA- 2020/10/29 06:00
PMCR- 2020/09/18
CRDT- 2020/09/18 17:12
PHST- 2019/09/13 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/18 17:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/10/29 06:00 [medline]
PHST- 2020/09/18 00:00 [pmc-release]
AID - PONE-D-19-25781 [pii]
AID - 10.1371/journal.pone.0238622 [doi]
PST - epublish
SO  - PLoS One. 2020 Sep 18;15(9):e0238622. doi: 10.1371/journal.pone.0238622. 
      eCollection 2020.